查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425125

单纯疱疹病毒治疗的全球市场：预测（2024-2029）

Herpes Simplex Virus Treatment Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球单纯疱疹病毒治疗市场规模预计在预测期内将以 4.12% 的复合年增长率成长。

疱疹，也称为单纯疱疹病毒 (HSV)，是一种引起疼痛的水痘和溃疡的常见疾病。口唇疱疹和单纯疱疹是由 1 型 (HSV-1) 引起的两种常见疾病，主要透过口腔接触传播。大多数人感染了 HSV-1。生殖器疱疹由 2 型 (HSV-2) 引起，透过性交传播。当口唇疱疹或生殖器疱疹症状再次出现时，您可能会感到不安。此外，生殖器疱疹还会影响性关係并造成尴尬。

单纯疱疹病毒治疗市场的成长动力

单纯疱疹病毒（HSV）感染频率的增加、抗病毒药物的可用性增加以及抗病毒抗药性的增加是推动单纯疱疹病毒治疗行业扩张的一些因素。研究和诊断技术的发展，以及作为预防措施的疫苗和局部杀菌剂的开发，进一步推动单纯疱疹病毒治疗市场的扩张。由于多种因素，HSV 治疗市场正在扩大，包括患者意识的提高、远端医疗医疗和数位医疗的采用、人口变化、持续的研发计划以及开发中国家单纯疱疹病毒治疗市场的扩大。

单纯疱疹病毒的传播

根据世界卫生组织（WHO）2023年4月发布的估计，全球50岁以下的人有37亿人感染口唇疱疹。67% ）被认为受到影响。单纯疱疹病毒 2 型 (HSV-2) 感染是生殖器疱疹的主要原因，影响着全世界 15 至 49 岁的估计 4.91 亿 (13%) 人。大多数疱疹感染是无症状或未确诊的，但疼痛的水痘和溃疡是疱疹的症状。感染 HSV-2 的人感染和传播 HIV 的风险增加。

越来越重视单纯疱疹病毒治疗

人们对治疗药物潜力的认识不断提高，推动了单纯疱疹病毒治疗市场的发展。新发或復发的疱疹感染通常用药物治疗。药物不能消除疾病，但可以减轻其严重程度和持续时间。復发性发作的治疗最好在症状出现后 48 小时内开始。常用的抗病毒药物包括伐昔洛韦、泛昔洛韦和阿昔洛韦。通常建议患有剧烈疼痛、频繁发作或希望降低将疱疹传播给他人的风险的人接受治疗。治疗疼痛的药物包括Ibuprofen、萘普生和乙酰胺酚（对乙酰胺酚）。可以使用利多卡因或Benzocaine因等药物来麻醉受影响的区域。

加大研发力度

由于单纯疱疹病毒 (HSV)感染疾病的慢性性、高发病率和病毒潜伏期，HSV 治疗的研究和开发至关重要。对潜伏病毒持有、抗病毒抗药性以及更有效的抗病毒药物的开发的研究正在进行中。最近的研究表明，HSV 复製需要特定的週期蛋白依赖型激酶(CDKS)。药物 CDK 抑制剂 (PCI) 可以透过多种方式阻断 HSV-1 感染。 PCI 阻断病毒 DNA 产生和基因表现的即时和早期刺激。

病毒学检测的普及

由于 HSV 可以在阴道溃疡和其他黏膜病变中检测到，因此 HSV NAAT 检测是最敏感的诊断方法，并且变得越来越可用。 FDA 批准了多种 HSV 检测测试，灵敏度范围为 90.9% 至 100%。中枢神经系统 (CNS) 疾病和全身性疾病（脑膜炎、脑炎、新生儿疱疹等）也最常使用 PCR 检测进行诊断。然而，血液中的 HSV PCR 检测不应用于检测生殖器疱疹感染，除非有广泛感染的风险（例如肝炎）。在这种情况下，唯一的病毒学测试是病毒培养。

改进诊断技术

诊断技术的进步永远改变了单纯疱疹病毒 (HSV) 检测和治疗的准确性和有效性。聚合酵素链锁反应(PCR) 测试可提供快速、准确的观察，包括有助于早期诊断和开始治疗的照护现场解决方案。血清学检测可揭示患者的感染史，基因序列测定可揭示病毒的类型以及可能对抗病毒药物的抗药性。微流体和生物感测器是新兴技术的例子，可以实现更快、更便宜的诊断。

北美单纯疱疹病毒治疗市场预计稳定成长

阿昔洛韦、伐昔洛韦和泛昔洛韦等抗病毒药物主导着北美单纯疱疹病毒治疗市场。这些药物旨在抑制和缓解 HSV-1 和 HSV-2 的症状。 HSV-1 和 HSV-2感染疾病的抑制治疗包括每天服用抗病毒药物，以减少 HSV-1 和 HSV-2感染疾病。-1/HSV-2 用于治疗感染疾病发生时的症状。为了降低感染风险，必须采取预防措施，例如安全性行为以及与伴侣讨论您的 HSV 状况。

单纯疱疹病毒治疗临床试验

  • 2023 年 9 月，美国卫生研究院宣布了单纯疱疹病毒研究策略计划，以解决单纯疱疹病毒 1 (HSV-1) 和 HSV-2 带来的持续健康风险。
  • 根据 BioNTech SE 发布的声明，2022 年 12 月，单纯疱疹病毒（HSV）候选疫苗 BNT163 将在首次人体试验中进行测试，用于预防由 HSV-2 和可能的 HSV-1 引起的阴道病变。是在一个分阶段的临床研究计划中进行的。本研究 (NCT05432583) 评估了 BNT163 的免疫抗原性、安全性和耐受性。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章单纯疱疹病毒治疗市场：依治疗分类

  • 介绍
  • 单纯疱疹病毒1
  • 单纯疱疹病毒2型

第六章 单纯疱疹病毒治疗市场：依药物分类

  • 介绍
  • 阿昔洛韦
  • 伐昔洛韦
  • 泛昔洛韦
  • 其他的

第七章 单纯疱疹病毒治疗市场：依最终使用者分类

  • 介绍
  • 医院药房
  • 零售药房
  • 网路药房

第八章单纯疱疹病毒治疗市场：依地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 併购/协议/合作

第十章 公司简介

  • A-Vax Technology
  • BioNTech
  • Mayo Clinic
  • Maruho
  • The Native Antigen Company
  • Cedars-Sinai
  • Kirk Eye Center
  • Rational Vaccines
  • Zovirax
简介目录
Product Code: KSI061616220

The herpes simplex virus treatment market is estimated to grow at a CAGR of 4.12% during the forecast period.

Herpes, also known as herpes simplex virus (HSV), is a common illness that can result in painful blisters or ulcers. Oral herpes and cold sores are two common illnesses caused by Type 1 (HSV-1) that are mostly transmitted through oral contact. The majority of people have HSV-1 infection. Genital herpes is caused by type 2 (HSV-2) and is transmitted during intercourse. It might be upsetting to experience recurrent oral or genital herpes symptoms. Additionally, genital herpes may affect sexual relationships and be stigmatizing.

Growth drivers for Herpes Simplex Virus Treatment Market

The increased frequency of herpes simplex virus (HSV) infections, the accessibility of antiviral drugs, and the rise in antiviral resistance are some of the factors propelling the expansion of the herpes simplex virus treatment industry. Further driving herpes simplex virus treatment market expansion are technological developments in research and diagnostics, as well as the creation of vaccines and topical microbicides as preventative measures. The market for HSV therapy is expanding due to several factors, including rising patient awareness, the incorporation of telemedicine and digital health, shifting demographics, continuous research and development initiatives, and herpes simplex virus treatment market expansion in developing nations.

Growing prevalence of herpes simplex virus

As per the World Health Organization estimates published in April 2023, the primary source of oral herpes, herpes simplex virus type 1 (HSV-1) infection, is thought to affect 3.7 billion persons under 50 (67%) worldwide. The primary cause of genital herpes, herpes simplex virus type 2 (HSV-2) infection, affects an estimated 491 million persons aged 15 to 49 globally (13%). The majority of herpes infections are asymptomatic or go undiagnosed, but painful blisters or ulcers that might eventually reoccur are signs of herpes. The risk of contracting and spreading HIV infection is elevated in individuals with HSV-2 infection.

Increasing emphasis on herpes simplex virus treatment

The growing awareness of possible medications for the treatment is fueling the herpes simplex virus treatment market. First-time or recurring herpes outbreaks are frequently treated with medications. They cannot eliminate the illness, but they can lessen its severity and duration. When treatment for recurring episodes is initiated within 48 hours of the onset of symptoms, the best results are achieved. Commonly prescribed antiviral medications include valacyclovir, famciclovir, and acyclovir. Those who have excruciating pain or recurring outbreaks often, or who wish to reduce their risk of spreading herpes to others, are frequently advised to seek treatment. Medication for soreness pain management includes ibuprofen, naproxen, and paracetamol (acetaminophen). Medications such as lidocaine and benzocaine might be used to numb the afflicted region.

Increasing R&D initiatives

The chronic nature, broad incidence, and viral latency of herpes simplex virus (HSV) infections make research and development (R&D) efforts for HSV therapy imperative. Research into latent virus reservoirs, antiviral resistance, and the development of more potent antiviral medications are all ongoing. Recent research studies have shown that HSV replication requires certain cyclin-dependent kinases (CDKS). There are many ways that pharmacological CDK inhibitors (PCIs) might stop HSV-1 infection. The PCIs halt the production of viral DNA and the immediate, and early stimulation of gene expression.

Growing utilization of virologic tests

Since HSV may be detected from vaginal ulcers or other mucocutaneous lesions, HSV NAAT assays are the most sensitive diagnostics; they are becoming more and more accessible. Although there are several FDA-cleared assays for HSV detection, their sensitivity ranges from 90.9% to 100%. Diseases of the central nervous system (CNS) and systemic diseases (such as meningitis, encephalitis, and newborn herpes) are also best diagnosed by PCR. However, blood HSV PCR testing should not be used to detect genital herpes infections unless there is a risk of a widespread infection (for example, hepatitis). In these situations, the sole virologic test available is viral culture.

Improvement in diagnostic technologies

The accuracy and efficacy of herpes simplex virus (HSV) detection and therapy have been completely transformed by developments in diagnostic technology. Rapid and accurate findings are provided by polymerase chain reaction (PCR) testing, including point-of-care solutions, which help with early diagnosis and treatment commencement. The history of a patient's exposure is established by serological testing, and the types of viruses and possible resistance to antivirals are revealed by genetic sequencing methods. Microfluidics and biosensors are examples of emerging technologies that show promise for even quicker and more affordable diagnostics.

The herpes simplex virus treatment market in the North American region is anticipated to grow steadily.

Antiviral drugs, such as acyclovir, valacyclovir, and famciclovir, are the mainstay of the herpes simplex virus treatment market in North America. These drugs are intended to control and lessen the symptoms of HSV-1 and HSV-2. While suppressive therapy entails taking antiviral medicine every day to lessen the frequency and severity of recurring outbreaks, episodic therapy is used to treat symptoms during outbreaks. Reducing the risk of transmission requires preventive measures, such as safe sexual practices and talking to partners about HSV status.

Herpes Simplex Virus Treatment Clinical Trials

  • In September 2023, the National Institutes of Health unveiled the Strategic Plan for Herpes Simplex Virus Research in response to the ongoing health risks posed by herpes simplex virus 1 (HSV-1) and HSV-2. The strategy was prepared by an NIH-wide HSV Working Group, which took into account input from over 100 members of the advocacy and scientific sectors as well as interested public stakeholders.
  • In December 2022, BNT163, a herpes simplex virus (HSV) vaccine candidate for the prevention of vaginal lesions caused by HSV-2 and maybe HSV-1, was dosed to the first patient in a first-in-human Phase 1 clinical research project, according to a statement released by BioNTech SE. The trial (NCT05432583) assessed BNT163's immunogenicity, safety, and tolerability.

Market Key Developments

  • In May 2023, Vyjuvek, a herpes simplex virus type 1 (HSV-1) vector-based gene therapy, was approved by the U.S. Food and Drug Administration to treat wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene and are at least six months of age.
  • In February 2023, CIBINQO® (abrocitinib) had a broader indication as the FDA approved Pfizer Inc.'s supplemental New Drug Application (sNDA). This allows adolescents (12 to <18 years old) with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is not advised.

Segmentation:

By Treatment

  • Herpes Simplex Virus-1
  • Herpes Simplex Virus-2

By Drug

  • Acyclovir
  • Valacyclovir
  • Famciclovir
  • Others

By End-User

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. HERPES SIMPLEX VIRUS TREATMENT MARKET BY TREATMENT

  • 5.1. Introduction
  • 5.2. Herpes Simplex Virus-1
  • 5.3. Herpes Simplex Virus-2

6. HERPES SIMPLEX VIRUS TREATMENT MARKET BY DRUG

  • 6.1. Introduction
  • 6.2. Acyclovir
  • 6.3. Valacyclovir
  • 6.4. Famciclovir
  • 6.5. Others

7. HERPES SIMPLEX VIRUS TREATMENT MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Retail Pharmacy
  • 7.4. Online Pharmacy

8. HERPES SIMPLEX VIRUS TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. A-Vax Technology
  • 10.2. BioNTech
  • 10.3. Mayo Clinic
  • 10.4. Maruho
  • 10.5. The Native Antigen Company
  • 10.6. Cedars-Sinai
  • 10.7. Kirk Eye Center
  • 10.8. Rational Vaccines
  • 10.9. Zovirax